Dna-pk inhibitors
US-2017258789-A1 · Sep 14, 2017 · US
DNA-PK inhibitors and uses thereof
US9925188B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9925188-B2 |
| Application number | US-201615056137-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 29, 2016 |
| Priority date | Apr 24, 2012 |
| Publication date | Mar 27, 2018 |
| Grant date | Mar 27, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of potentiating a therapeutic regimen for the treatment of breast cancer, colorectal cancer, gastric-esophageal cancer, fibrosarcoma, glioblastoma, hepatocellular carcinoma, head and neck squamous cell carcinoma, melanoma, lung cancer, pancreatic cancer, or prostate cancer in a patient comprising the step of administering to said patient an effective amount of a compound or a pharmaceutical composition comprising said compound, wherein the compound is or a pharmaceutically acceptable salt thereof. 2. The method of claim 1 , wherein the compound is represented by the following formula: or a pharmaceutically acceptable salt thereof. 3. The method of claim 1 , wherein the compound is represented by the following formula: or a pharmaceutically acceptable salt thereof. 4. The method of claim 1 , wherein the compound is represented by the following formula: or a pharmaceutically acceptable salt thereof. 5. The method of claim 4 , wherein the compound is represented by the following formula: 6. The method of claim 1 , wherein the compound is represented by the following formula: or a pharmaceutically acceptable salt thereof. 7. The method of claim 1 , wherein the compound is represented by the following formula: or a pharmaceutically acceptable salt thereof. 8. The method of claim 1 , wherein the compound is represented by the following formula: or a pharmaceutically acceptable salt thereof. 9. The method of claim 1 , wherein the compound is represented by the following formula: or a pharmaceutically acceptable salt thereof. 10. The method of claim 9 , wherein the compound is represented by the following formula: 11. The method of claim 1 , wherein the compound is represented by the following formula: or a pharmaceutically acceptable salt thereof. 12. The method of claim 1 , wherein the compound is represented by the following formula: or a pharmaceutically acceptable salt thereof. 13. The method of claim 1 , wherein the pharmaceutical composition is orally administered to the patient. 14. The method of claim 1 , wherein the pharmaceutical composition is a capsule, tablet, or aqueous suspension. 15. The method of claim 14 , wherein the pharmaceutical composition is a capsule. 16. The method of claim 14 , wherein the pharmaceutical composition is a tablet. 17. The method of claim 1 , wherein the therapeutic regimen comprises radiation therapy. 18. The method of claim 1 , wherein the therapeutic regimen comprises an anti-cancer therapeutic agent.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
specific for leukemia · CPC title
- C07D401/14Primary
containing three or more hetero rings · CPC title
Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy (radiotherapy per se A61N5/10) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9925188B2 cover?
- The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
- Who is the assignee on this patent?
- Vertex Pharma
- What technology area does this patent fall under?
- Primary CPC classification C07D401/14. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 27 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 10 related publications on this page (citations in our corpus or others sharing the same primary CPC).